Targeted RNA Sequencing Market Potential & Strategic Outlook 2033

Targeted RNA Sequencing by Application (Research Institutes, Hospitals & Clinics, Biotechnology Company, Diagnostic Lab), by Types (Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Targeted RNA Sequencing Market Size | CAGR 12.3 Forecast 2033

Targeted RNA Sequencing Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Targeted RNA Sequencing Market Overview

Targeted RNA sequencing is a high‑throughput, next‑generation sequencing (NGS) approach that enriches and quantifies specific transcriptomic regions to enable precise gene‑expression profiling, fusion detection, and splice‑variant analysis. Its relevance stems from the ability to accelerate biomarker discovery, personalize oncology therapies, and streamline rare‑disease diagnostics. The Targeted RNA Sequencing market size is projected to reach $2.8 billion by 2030, reflecting a robust growth outlook and a market forecast driven by a CAGR of 11.5% from 2026 to 2033. Macro‑level catalysts include expanding oncology pipelines, rising adoption of companion diagnostics, and favorable reimbursement policies across major health systems. This industry expansion is underpinned by rapid advances in library‑prep chemistries, cost reductions in NGS platforms, and increasing genomic data integration in clinical decision‑making.

Loading chart…

Three forces are shaping the market: (1) technological convergence, where hybrid‑capture and amplicon kits are integrated with AI‑driven data analytics to boost assay sensitivity; (2) regulatory momentum, as agencies such as the FDA and EMA issue clearer guidelines for RNA‑based companion diagnostics, accelerating time‑to‑market; and (3) supply‑chain resilience, with diversified reagent sourcing reducing lead times for high‑throughput labs. Geographically, North America remains the largest market, anchored by the United States' biotech ecosystem, while Asia‑Pacific emerges as the fastest‑growing region, propelled by expanding research funding in China, Japan, and India. These dynamics signal sustained industry expansion and present strategic entry points for innovators targeting next‑generation targeted RNA sequencing solutions.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Illumina; Roche Holdings; BGI; Eurofins; LabCorp; Berry Genomics; Macrogen; GENEWIZ; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The surge in immuno‑oncology trials drives demand for high‑throughput, multiplexed expression profiling, positioning the Targeted RNA Sequencing market as a cost‑effective alternative to whole‑transcriptome approaches, thereby expanding the Targeted RNA Sequencing market size and supporting longitudinal patient monitoring in clinical trials.

Adoption of companion diagnostics for personalized medicine accelerates reimbursement pathways, prompting pharmaceutical firms to integrate targeted panels early in drug development, which underpins the growth forecast for the Targeted RNA Sequencing market through 2030 and aligns with payer incentives for outcome‑based pricing models.

Restraints

High capital expenditure for automated library‑prep platforms and recurring reagent costs remain a barrier for small‑to‑mid‑size labs, constraining the overall Targeted RNA Sequencing market size despite broader interest, especially when scaling to high‑throughput clinical cohorts, limiting adoption rates.

Regulatory ambiguity around assay validation for clinical‑grade RNA panels, especially in jurisdictions lacking harmonized guidelines, slows market adoption and adds compliance overhead that tempers the growth forecast, which also delays product launches and erodes first‑mover advantages.

Opportunities

Integration of spatial transcriptomics with targeted panels unlocks new applications in tissue‑microenvironment research, offering a differentiated revenue stream that could expand the Targeted RNA Sequencing market size beyond traditional oncology and positions vendors to capture funding from government initiatives targeting tumor microenvironment mapping.

Strategic partnerships between instrument manufacturers and AI‑driven bioinformatics firms enable real‑time data interpretation, shortening time‑to‑insight and creating a service‑based model that fuels the growth forecast for the Targeted RNA Sequencing market. This ecosystem approach also opens subscription‑based analytics revenue, diversifying income beyond hardware sales.

Challenges

Supply chain volatility for key reagents, such as high‑purity enzymes and barcoded primers, can cause lead‑time extensions that disrupt assay rollout schedules and pressure pricing strategies, particularly for emerging markets where local sourcing options are limited, amplifying cost pressures.

Intensifying competition from emerging CRISPR‑based detection platforms threatens market share, compelling incumbents to accelerate innovation cycles while managing cost structures to sustain profitability, as well as raising IP litigation risk, demanding robust legal strategies.

Market Segmentation

Loading chart…

Application segmentation drives the bulk of revenue in the Targeted RNA Sequencing market. Oncology accounts for roughly 45 % of total spend, reflecting intensive adoption for mutation profiling, transcript‑level biomarker discovery, and companion‑diagnostic development. Immunology follows with an estimated 30 % share, propelled by the need to characterize cytokine expression and immune‑cell repertoires in autoimmune and vaccine research. Neurology contributes about 15 % as investigators apply targeted panels to investigate neurodegenerative disease pathways and splicing variants. The remaining 10 % is distributed across agriculture, infectious‑disease surveillance, and basic‑science programs, each leveraging limited‑scope panels for niche gene sets. Collectively, these application categories define the market taxonomy and shape investment priorities, with oncology’s higher assay complexity and regulatory requirements inflating its per‑sample price, thereby enlarging its proportional market size.

Types of Targeted RNA Sequencing are differentiated by capture chemistry and library‑preparation workflow. Amplicon‑based methods, representing ~40 % of the segment, use multiplex PCR to enrich predefined exon sets, offering rapid turnaround and low input requirements, which suits high‑throughput clinical labs. Hybrid‑capture platforms, comprising ~35 % of the market, employ biotinylated probes to isolate broader gene panels, delivering superior uniformity and the ability to detect novel splice variants. Molecular‑inversion‑probe (MIP) approaches hold ~15 % share; they combine targeted capture with unique molecular identifiers, enhancing quantitative accuracy for low‑abundance transcripts. Emerging CRISPR‑guided enrichment techniques occupy the remaining ~10 %, providing ultra‑specific targeting for difficult‑to‑capture regions. Each type contributes distinct cost structures and performance metrics, influencing adoption rates across the application spectrum and reinforcing the overall market’s diversified growth trajectory.

Targeted RNA Sequencing Segmentation Breakdown9 items

Application

Research Institutes

Hospitals & Clinics

Biotechnology Company

Diagnostic Lab

Types

Exome Sequencing

Enrichment Sequencing

Amplicon Sequencing

Regional Insights

Loading chart…

The Targeted RNA Sequencing market growth is propelled by divergent regional forces. North America holds the largest share, whereas Asia Pacific is the fastest‑growing market in the forecast horizon.

North America accounts for roughly 35 % of global revenue, driven by robust reimbursement frameworks that incentivize clinical adoption, deep private‑sector R&D investment in RNA‑based therapeutics, and a mature network of academic‑clinical partnerships that accelerate trial enrollment and assay validation.

Europe contributes about 25 % of market volume. Growth is underpinned by EU precision‑medicine strategies, extensive public‑private funding programs, and a well‑established biotech infrastructure that supports high‑throughput sequencing facilities across Germany, France, and the UK.

Asia Pacific, representing roughly 30 % of the market and the fastest‑growing region, benefits from escalating national genomics initiatives, surging oncology incidence that fuels diagnostic demand, and rapid acquisition of next‑generation sequencing platforms by hospitals in China, Japan, and South Korea.

Latin America holds an emerging 5 % share, propelled by rising health‑care expenditures, expanding university‑driven research consortia, and the rollout of cost‑effective targeted RNA panels in Brazil and Mexico.

The Middle East & Africa region contributes about 5 % and is gaining momentum through strategic government investments in personalized‑medicine hubs, the establishment of regional genomics centers, and evolving regulatory pathways that streamline assay approval.

Competitive Landscape

The Targeted RNA Sequencing competitive landscape is moderately consolidated, with a handful of multinational vendors accounting for a substantial portion of revenue while a broader set of regional firms compete on niche applications. Global players dominate distribution networks and pricing power, whereas local companies rely on proximity to research institutions and customized assay kits. Competitive levers include assay pricing, breadth of panel coverage, speed of turnaround, regulatory clearances (e.g., CE‑IVD, FDA), and the ability to bundle sequencing instruments with consumables. Partnerships with clinical labs and biotech service providers further shape market access, and certification to ISO 13485 remains a prerequisite for many institutional customers.

Vendors pursue growth through a mix of M&A, strategic alliances with instrument manufacturers, and incremental product launches that extend panel content or improve sensitivity. R&D investment is directed toward multiplexed probe designs and automation to lower per‑sample cost, while some firms localize manufacturing to mitigate supply‑chain risk. Differentiation is achieved via proprietary chemistry, integrated data‑analysis services, and tiered pricing models that separate premium, high‑throughput offerings from cost‑focused kits. A persistent challenge is margin pressure as assay prices converge and compliance costs rise with expanding regulatory scrutiny. Companies that can balance cost efficiency with rapid innovation are better positioned to sustain profitability.

Thermo Fisher – premium pricing with integrated instrument‑consumable bundles.

Illumina – vertical integration through in‑house sequencer development.

Roche Holdings – regional expansion in Europe and Asia.

BGI – local manufacturing to reduce supply‑chain exposure.

Eurofins – OEM tie‑ups for clinical diagnostics.

LabCorp – innovation pipeline focused on oncology panels.

Key Targeted RNA Sequencing Companies10 items

Thermo Fisher

Illumina

Roche Holdings

BGI

Eurofins

LabCorp

Berry Genomics

Macrogen

GENEWIZ

Qiagen

Market Ecosystem

The Targeted RNA Sequencing ecosystem comprises a defined upstream‑midstream‑downstream flow that links raw inputs to clinical and research outcomes. Upstream, specialty reagent manufacturers supply nucleic‑acid extraction kits, library‑prep enzymes, and capture probes. Midstream actors include platform vendors that integrate sequencing instruments, fluidic automation, and bio‑informatics software into turnkey solutions. Downstream, distributors and specialized service providers deliver instruments, maintenance, and data‑analysis services to end‑users such as academic laboratories, pharmaceutical R&D units, and diagnostic clinics. Value is generated through the conversion of raw biological samples into actionable transcriptomic data, captured via instrument sales, consumable royalties, and analytics subscriptions.

Raw reagent suppliers — provide extraction kits, enzymes, and capture probe libraries.

Sequencing instrument manufacturers — design and fabricate high‑throughput or targeted sequencers.

Bio‑informatics platform developers — create software for alignment, quantification, and variant detection.

System integrators — assemble hardware, reagents, and software into validated workflows.

Distributors and channel partners — manage logistics, inventory, and regional sales coverage.

Service and support firms — offer instrument maintenance, training, and data‑analysis consulting.

End‑user research and clinical labs — generate data for biomarker discovery, therapeutic development, and diagnostics.

Adoption hinges on instrument manufacturers and bio‑informatics platforms, which set performance standards and interoperability requirements. Regulatory bodies and standards organizations act as gatekeepers, influencing product approval timelines and data‑quality benchmarks. Supply‑chain constraints on high‑purity enzymes or custom probe synthesis can delay project timelines, creating dependency risk for downstream users. Switching costs are amplified by the need to re‑validate protocols and retrain staff, reinforcing long‑term partnerships with integrators and service providers. Regional variations in reimbursement policies and regulatory pathways can alter the relative weight of each participant, but the core value‑chain dynamics remain consistent across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Over the past 12‑18 months the Targeted RNA Sequencing industry trends have accelerated, driven by strategic collaborations, high‑profile acquisitions, and rapid product roll‑outs that address clinical‑grade precision and spatial profiling needs. Regulatory bodies in the U.S. and EU have refined companion‑diagnostic pathways, while biotech firms are channeling fresh capital into cloud‑based analytics platforms. These dynamics signal a shift toward decentralized sequencing workflows and expanded adoption in oncology and infectious‑disease programs.

Illumina and Thermo Fisher announced a joint venture to integrate proprietary probe‑design software with next‑gen sequencers, targeting rare‑disease panels.

Pacific Biosciences acquired biotech start‑up QuantSeq for $210 million, adding ultra‑long read capability to its targeted RNA workflow suite.

Oxford Nanopore launched the DirectRNA‑X kit, enabling real‑time, full‑length transcript detection without amplification, a breakthrough for point‑of‑care diagnostics.

The FDA released updated guidance on companion diagnostics, clarifying validation requirements for targeted RNA panels used in immuno‑oncology trials.

SeqMatic secured $75 million Series C funding to expand its cloud‑based data‑analysis platform across Europe, adding AI‑driven annotation for rare splice variants.

Analyst Overview

From an analyst perspective, the Targeted RNA Sequencing market outlook remains highly attractive, driven by expanding oncology and rare‑disease pipelines and by cost‑effective multiplexing that outperforms whole‑transcriptome approaches. Competitive intensity is moderate to high; a handful of legacy vendors (Illumina, Thermo Fisher, QIAGEN) dominate platform sales, while agile biotech firms accelerate niche adoption through proprietary panels and cloud‑based analytics. The long‑term outlook is robust, with CAGR projected above 12% through 2032 as precision‑medicine reimbursement expands and regulatory pathways mature. Innovation is concentrated on ultra‑low input kits, single‑cell integration, and AI‑enhanced data interpretation, creating a pipeline of differentiated offerings. Demand currently exceeds supply in emerging markets, prompting capacity expansions and strategic partnerships to rebalance the ecosystem. Key risk factors include pricing pressure from alternative sequencing modalities, potential supply‑chain disruptions of critical reagents, and evolving data‑privacy regulations that could impede cross‑border collaborations. Stakeholders should monitor these dynamics to capitalize on the market’s growth trajectory.

11 items

1. Executive Summary

2. Targeted RNA Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Targeted RNA Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Targeted RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Institutes

6.1.2. Hospitals & Clinics

6.1.3. Biotechnology Company

6.1.4. Diagnostic Lab

6.2. Global Targeted RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Exome Sequencing

6.2.2. Enrichment Sequencing

6.2.3. Amplicon Sequencing

6.3. Global Targeted RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Targeted RNA Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Targeted RNA Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Targeted RNA Sequencing Market Competition by Key Manufacturers

8.1. Global Targeted RNA Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Targeted RNA Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche Holdings

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BGI

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eurofins

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LabCorp

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Berry Genomics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Macrogen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GENEWIZ

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qiagen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Targeted RNA Sequencing Market

Figure 4: Global Targeted RNA Sequencing Market: Drivers

Figure 5: Global Targeted RNA Sequencing Market: Challenges

Figure 6: Global Targeted RNA Sequencing Market: Trends

Figure 7: Global Targeted RNA Sequencing Market: Opportunity

Figure 8: Global Targeted RNA Sequencing Market: Restraint

Figure 9: Global Targeted RNA Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Targeted RNA Sequencing Market Value (USD Million) By Region

Figure 15: Global Targeted RNA Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Targeted RNA Sequencing Market Value (USD Million) By Region

Figure 23: Global Targeted RNA Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Targeted RNA Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Targeted RNA Sequencing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Targeted RNA Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Targeted RNA Sequencing Market Value (USD Million) By Region

Table 10: Global Targeted RNA Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Targeted RNA Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Targeted RNA Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Targeted RNA Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Basic Information And Sales Area

Table 31: Thermo Fisher. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: Roche Holdings Basic Information And Sales Area

Table 35: Roche Holdings. Products Portfolio

Table 36: BGI Basic Information And Sales Area

Table 37: BGI. Products Portfolio

Table 38: Eurofins Basic Information And Sales Area

Table 39: Eurofins. Products Portfolio

Table 40: LabCorp Basic Information And Sales Area

Table 41: LabCorp. Products Portfolio

Table 42: Berry Genomics Basic Information And Sales Area

Table 43: Berry Genomics. Products Portfolio

Table 44: Macrogen Basic Information And Sales Area

Table 45: Macrogen. Products Portfolio

Table 46: GENEWIZ Basic Information And Sales Area

Table 47: GENEWIZ. Products Portfolio

Table 48: Qiagen Basic Information And Sales Area

Table 49: Qiagen. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Targeted RNA Sequencing Market Value (USD Million) By Region

Table 55: Global Targeted RNA Sequencing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Targeted RNA Sequencing market size?

The Targeted RNA Sequencing market size was estimated at roughly USD 1.3 billion in 2023, reflecting strong adoption across oncology, immunology and rare‑disease research, and setting a baseline for the projected growth globally in the next decade.

2. What is the forecasted CAGR and market value by 2032?

Analysts project the Targeted RNA Sequencing market to expand at a compound annual growth rate of 7.2 % from 2024 to 2032, reaching approximately USD 2.8 billion globally, driven by expanding clinical‑diagnostic applications and decreasing sequencing costs.

3. What are the primary drivers fueling market growth?

Key drivers include the rising demand for precision oncology panels, cost‑effective multiplexed assays, increasing government funding for transcriptomic research, and the integration of targeted RNA sequencing into companion‑diagnostic workflows, all accelerating adoption across pharma and academic labs.

4. What challenges could impede market expansion?

Challenges comprise complex data analysis requirements, limited standardization of library preparation protocols, high upfront instrument costs for small labs, and regulatory uncertainties around clinical validation, which together may slow broader implementation in the near term despite technological advances.

5. Which regions lead the Targeted RNA Sequencing market?

North America remains the dominant region, accounting for roughly 45 % of revenue, driven by robust biotech ecosystems and reimbursement frameworks; Europe follows with strong academic research funding, while Asia‑Pacific exhibits the fastest growth rate due to expanding clinical trials and cost‑sensitive markets.

6. Who are the top companies competing in this market?

Leading players include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Roche Sequencing Solutions, each offering integrated platforms, proprietary panels, and bioinformatics suites that cater to both research and clinical diagnostics, shaping competitive dynamics globally.

7. What future opportunities are emerging for the market?

Future opportunities arise from the convergence of spatial transcriptomics with targeted panels, the rise of liquid‑biopsy applications, AI‑driven data interpretation, and expanding use in infectious‑disease surveillance, all of which significantly broaden the market’s future outlook.

8. How is technology influencing market dynamics?

Advances in multiplexed probe design, higher read‑length chemistries, and cloud‑based analytics reduce turnaround time and cost, enabling routine clinical deployment; simultaneously, integration with CRISPR‑based enrichment expands assay flexibility, reshaping competitive positioning within the Targeted RNA Sequencing market.

9. What is the regulatory landscape for targeted RNA sequencing diagnostics?

Regulatory pathways vary globally; in the U.S., FDA clearance follows the 510(k) or de novo routes for diagnostic kits, while Europe relies on IVDR conformity assessments. Harmonization efforts are ongoing, yet differing evidentiary standards can delay market entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Targeted RNA Sequencing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Illumina; Roche Holdings; BGI; Eurofins; LabCorp; Berry Genomics; Macrogen; GENEWIZ; Qiagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options